News

Bryostatin, Neurotrope Bioscience’s investigational therapy, was associated with improved cognition in advanced Alzheimer’s disease patients in post-hoc (after-the-fact) analysis of a Phase 2 trial. Results from this study were presented at the Sachs’ Neuroscience Innovation Forum on Jan. 7 in San Francisco, California. Bryostatin-1 is a compound known as…

A new algorithm can quantify faster and more effectively the amount of brain amyloid plaques during positron emission tomography (PET) scans for use in subject stratification and clinical trials of Alzheimer’s disease, according to the developers. The new technique, developed by Invicro, was presented earlier this year at the…

Roche soon will start two Phase 3 trials testing gantenerumab, its amyloid-targeting treatment candidate, in prodromal, or early, Alzheimer’s patients. Each plans to enroll 750 people, ages 50 to 90, and will judge gantenerumab’s effectiveness and potential clinical benefit by looking at changes in dementia and amyloid plaque load…

This year’s one-million-euro Nobel of Neuroscience has been split among four European biologists whose research has pinned down the origins of Alzheimer’s disease. The winners of the Lundbeck Foundation Brain Prize are: • Michel Goedert, head of neurobiology at Cambridge University’s Laboratory of Molecular Biology. • Bart De Strooper, director of…

Clairvoyant Networks is accepting pre-orders for Theora Care, a new line of caregiver solutions designed to locate and connect with loved ones living with conditions like dementia, memory loss, or Alzheimer’s disease. The devices are expected to be launched this spring, according to the company’s website. Clairvoyant presented Theora Care…

The safety and efficacy of Roche’s gantenerumab, a treatment candidate for Alzheimer’s, will be tested in two global Phase 3 clinical trials in patients with early to mild forms of the disease. The studies follow a long research process that defined the therapy’s optimal dose. The GRADUATE1 (NCT03444870) and GRADUATE2…

Having one hour a week of social interaction, combined with a just a small amount of personalized care, can improve the quality of life of people with dementia who live in care homes, according to a recent study in the United Kingdom. These findings came from the Improving Wellbeing and…

The U.S. Food and Drug Administration has revised clinical trial guidelines for Alzheimer’s therapies to help researchers come up with trial objectives that are better suited to patients in the early stages of the disease. European regulators have also revised their Alzheimer’s trial guidelines. The early-stage patients that the new…

Those caring for people with dementia often feel they don’t have a support system that can help them cope with their burden, a British study reports. The lack of support leads to stress, isolation and feelings of guilt, researchers said. One thing that could help, the University of Lincoln team suggested, was…

AbbVie and Voyager Therapeutics are teaming up to develop antibody-based gene therapies for Alzheimer’s and other neurodegenerative disorders. The collaboration includes gene therapies against the harmful tau protein in the brains of Alzheimer’s patients. An antibody is a protein the immune system generates to fight harmful substances. Companies can…